首页> 外文期刊>Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases >Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment
【24h】

Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment

机译:中国基因型1b慢性丙型肝炎患者干扰素治疗失败的病毒序列演变

获取原文
获取原文并翻译 | 示例
           

摘要

The efficiencies of IFN-alpha based therapy in chronic genotype 1b HCV patients are still unsatisfied to date. The mechanisms underlining treatment failure remain unclear and controversial. To investigate HCV sequence evolution in unsuccessfully treated genotype 1b patients before, during and after the therapy, full-length open-reading-frame of HCV genomes at week 0, week 48 and year 5 in one breakthrough and one nonresponse patients were amplified by reverse transcription (RT)-nested-PCR and sequenced. Mutations were scored and analyzed according to their locations in the HCV genome. HCV sequences in the breakthrough patient displayed significantly more mutations during the one-year therapy than that in the nonresponse patient, with p7 and NS2 encoding regions having the highest mutation rates. Most of the mutations selected during the therapy phase in the breakthrough patient were maintained and few new mutations arose in the four-year post-therapy phase, suggesting these mutations might not compromise viral fitness. Altogether our data suggest that mutations occurred during the therapy phase in the breakthrough patient are likely driven by the action of interferon and ribavirin, and these mutations may have important effects on the responses to interferon based therapy in genotype 1b HCV patients
机译:迄今为止,基于IFN-α的治疗在慢性基因型1b HCV患者中的效率仍不令人满意。强调治疗失败的机制尚不清楚,并存在争议。为了研究未成功治疗的基因型1b患者在治疗之前,期间和之后的H​​CV序列演变,在一次突破中在0周,48周和5年时HCV基因组的全长开放阅读框,并通过反向扩增1位无反应的患者转录(RT)嵌套式PCR并测序。根据突变在HCV基因组中的位置对突变进行评分和分析。在一年的治疗中,突破性患者的HCV序列显示出比无应答患者显着更多的突变,其中p7和NS2编码区的突变率最高。突破性患者在治疗阶段选择的大多数突变均得以保留,并且在治疗后的四年中几乎没有出现新的突变,这表明这些突变可能不会损害病毒的适应性。总的来说,我们的数据表明突破性患者在治疗阶段发生的突变可能是由干扰素和利巴韦林的作用驱动的,并且这些突变可能对基因型1b HCV患者对基于干扰素的治疗产生重要影响

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号